What Ovarian ADCs Still Need to Deliver

Although antibody drug conjugates have generated real optimism in ovarian cancer, the faculty stress that several key questions remain unresolved before their long term value can be fully defined. Response rates in platinum resistant disease are encouraging, but clinicians also want to see durable benefit, preservation of quality of life, and meaningful survival outcomes. Duration of therapy becomes especially important because these agents still deliver potent cytotoxic payloads, and prolonged treatment may carry cumulative consequences that are not yet fully understood. The conversation also returns to the lack of strong maintenance options for some patient groups, especially those with homologous recombination proficient disease, where better strategies are urgently needed. Overall survival is emphasized as a critical endpoint for future trials, particularly if these therapies move into earlier lines or longer treatment windows. The faculty view antibody drug conjugates as promising tools rather than finished solutions. Continued research will need to clarify which patients benefit most, how long treatment should continue, and how these therapies affect the broader course of care.